UroToday Appoints Thomas E. Keane as Editor-in-Chief

Share Article

A well-respected global leader in his field, Dr. Keane is poised to contribute fresh and honest insights to UroToday's worldwide audience.

Thomas E Keane

Thomas E. Keane, MD

I hope to continue the work of my predecessors in bringing the most up-to-date information available from all aspects of urology to urologists -- in all settings and on an international scale.

We are pleased and privileged to announce that Dr. Thomas E. Keane is the new editor-in-chief of UroToday. A well-respected global leader in his field, Dr. Keane is poised to contribute fresh and honest insights to our worldwide audience, and he will provide a U.S. as well as a global perspective on new and developing research in the field of urology.

Dr. Keane will author a new monthly column sharing his thoughts on new developments and a perspective on their potential impact on urology.

Thomas E. Keane, MBBCh, FRCSI, FACS, was born and educated in Dublin. He subsequently moved to the U.S. where he has held positions at Duke University in Durham, NC and Emory University in Atlanta, GA. Since 2002, Dr. Keane has resided in Charleston, NC and serves as professor and chairman of the Department of Urology at the Medical University of South Carolina where he specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or co-investigator on more than 20 major clinical and preclinical studies, which have been funded by grants from the National Institutes of Health, as well as private industry. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies, with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a U.S. patent for BNCT in prostate cancer and sphingolipid derivatives and their use. Dr. Keane’s research has led to publication of more than 100 peer-reviewed articles in journals such as Cancer Research, Journal of Urology, Urologic Oncology, and the Journal of Clinical Investigation.

We look forward to Dr. Keane shaping the next decade of UroToday. A quote that reflects Dr. Keane’s outlook on life, and also is very appropriate for physicians, is by Winston Churchill, “we make a living by what we get, but we make a life by what we give.”

About UroToday

UroToday is an online medical resource that focuses on genitourinary cancers, as well as all other urologic health conditions impacting men and women. Based in Berkeley, California, the website was founded in 2003 by Gina Carithers, CEO and publisher of its parent company, Digital Science Press, Inc. With more than 250 new content items posted every week, UroToday.com is the world’s largest and most comprehensive online urology-oncology resource and is accessible, at no charge, to readers around the globe. Digital Science Press also publishes the UroToday International Journal (UIJ), a peer-review online journal that features articles on all urological topics and includes original research, review articles, and case studies.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gina Carithers
@urotoday
since: 02/2009
Follow >
UroToday
Like >
UroToday, Inc.

Visit website